Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials.

Authors: Happe, Myra, Hofstetter, Amelia R., Wang, Jing, Yamshchikov, Galina V., Holman, LaSonji A., Novik, Laura, Strom, Larisa, Kiweewa, Francis, Wakabi, Salim, Millard, Monica, Kelley, Colleen F., Kabbani, Sarah, Edupuganti, Srilatha, Beck, Allison, Kaltovich, Florence, Murray, Tamar, Tsukerman, Susanna, Carr, Derick, Ashman, Carl, Stanley, Daphne A.

Source: NPJ Vaccines; 3/29/2024, Vol. 9 Issue 1, p1-11, 11p

Subject Terms: EBOLA virus, EBOLA virus disease, VACCINIA, VACCINES, VIRUS diseases, ANTIBODY formation

Geographic Terms: UGANDA

A single-shot ChAd3-MARV vaccine confers rapid and durable protection against Marburg virus in nonhuman primates.

Authors: Hunegnaw, Ruth, Honko, Anna N., Wang, Lingshu, Carr, Derick, Murray, Tamar, Shi, Wei, Nguyen, Lam, Storm, Nadia, Dulan, Caitlyn N. M., Foulds, Kathryn E., Agans, Krystle N., Cross, Robert W., Geisbert, Joan B., Cheng, Cheng, Ploquin, Aurélie, Stanley, Daphne A., Geisbert, Thomas W., Nabel, Gary J., Sullivan, Nancy J.

Source: Science Translational Medicine; 12/14/2022, Vol. 14 Issue 675, p1-12, 12p

Subject Terms: EBOLA virus, MARBURG virus, HEMORRHAGIC fever, VACCINE effectiveness, PRIMATES, PRIMATE diseases

Geographic Terms: WEST Africa

Company/Entity: CENTERS for Disease Control & Prevention (U.S.), NATIONAL Institute of Allergy & Infectious Diseases (U.S.)

This result is not displayed to guests.
Login for full access.